| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
11 analysts have expressed a variety of opinions on Johnson & Johnson (NYSE:JNJ) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 8 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 3 | 2 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $184.27, a high estimate of $215.00, and a low estimate of $167.00. This upward trend is apparent, with the current average reflecting a 2.82% increase from the previous average price target of $179.22.
The standing of Johnson & Johnson among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Shagun Singh | RBC Capital | Maintains | Outperform | $175.00 | $175.00 |
| Shagun Singh | RBC Capital | Maintains | Outperform | $175.00 | $175.00 |
| Shagun Singh | RBC Capital | Maintains | Outperform | $175.00 | $175.00 |
| Shagun Singh | RBC Capital | Maintains | Outperform | $175.00 | $175.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Morten Herholdt | HSBC | Raises | Buy | $170.00 | $169.00 |
| Terence Flynn | Morgan Stanley | Lowers | Equal-Weight | $167.00 | $168.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $175.00 | $181.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | - |
| Geoff Meacham | B of A Securities | Lowers | Neutral | $170.00 | $180.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | - |
For valuable insights into Johnson & Johnson's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Johnson & Johnson analyst ratings.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Johnson & Johnson's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 2.34%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Johnson & Johnson's net margin is impressive, surpassing industry averages. With a net margin of 15.22%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Johnson & Johnson's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.69% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Johnson & Johnson's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.92%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.48, Johnson & Johnson adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: JNJ
